Systematic Review
The reported incidences of co-participation of Mycoplasma capricolum capripneumoniae (Mccp) and Pasteurella multocida in increased severity and pathogenesis of goats with Contagious caprine pleuropneumonia (CCPP) in sub-Saharan Africa elicited the study’s purpose. Using the preferred reporting items for systematic review and meta-analysis (PRISMA) guideline, two search engines, namely Google Scholar and PubMed, were queried to systematically review all the available literature on the current epidemiological status of CCPP and Pneumonic Pasteurellosis co-concurrently detected in goats and assess the available treatment and control measures and their challenges in the Sub-Saharan region. The search was limited to papers published between 1998 and 2024, whereby only peer-reviewed English articles were included in the study. Review papers, papers displaying abstracts only, duplicated information, papers beyond the sub-Saharan Africa region and papers published in other languages were excluded from the study. Only articles with full text and focused on goats were included for further screening process and review. A total of 3311 articles were retrieved from both databases, whereas only 58 articles met the inclusion criteria and hence were included in the data analysis. Only eight countries namely, Ethiopia, Kenya, Uganda, Nigeria, Sudan, Eritrea, Zambia and Tanzania reported the occurrence of CCPP and or Pasteurellosis: Ethiopia 23/58(39%), Tanzania 18/58 (31%), 1/58(2%) Nigeria, 1/58(2%) Zambia, 1/58(2%) Eritrea, Uganda 2/58 (3%), 2/58(3%) Sudan and Kenya 10/58(16%). Only 5/58 (9%) reported the occurrence of pneumonic pasteurellosis in Nigeria and Ethiopia. Only Tanzania (75%) and Ethiopia (33%) reported Mccp and Pasteurella multocida co-isolation and/ or detection in CCPP cases. Information on the antimicrobial susceptibility profile of Mccp and Pasteurella multocida from Sub-Saharan Africa was unavailable. One vaccine against CCPP, namely F-38 inactivated, and one vaccine against pneumonic pasteurellosis were identified to be developed and used in Sub-Saharan Africa. Developing bivalent candidate vaccines for both etiological agents is highly recommended.